Free Light Chains of Immunoglobulin as a Prognostic Factor for Some Plasmaproliferative Diseases

Open access

Free Light Chains of Immunoglobulin as a Prognostic Factor for Some Plasmaproliferative Diseases

Quantitation of monoclonal immunoglobulins and their fragments is used for monitoring the plasmaproliferative disease course and the effect of therapy. The aim of free light chains examination was to evaluate the significance of the FLC ratio as a prognostic factor for remission, progression and survival in different disease groups. The concentrations of immunoglobulins and free light chains were measured by an immunonephelometric method on a »SIEMENS« DADE BN II analyser with reagents (Freelite, The Binding Site, UK). In this examination 151 patients from 3 different disease groups: 1. Light chain disease or Bence Jones myeloma (37), 2. Biclonal gammopathy with FLC (23) and 3. Monoclonal gammopathy of undetermined significance (91), were investigated during a period of 7 years. The reference interval for FLC ratio is 0.26-1.65. According to the International Staging System for multiple myeloma, a serum FLC ratio of <0.03 or >32 was taken as abnormal. The patients with light chain disease and biclonal gammopathy with FLC with an abnormal FLC ratio and a combination of adverse risk factors (76.7%) had median survival times of 22-30 months, versus patients with a normal or slightly varied FLC ratio without adverse risk factors (23.3%) with median survival times of 39-51 months. About 38% of patients who had shown lowered free light chains values by more than 50% under therapy, achieved disease remission in the light chain disease and biclonal gammopathy with FLC groups. In the group of patients with monoclonal gammopathy of undetermined significance, 66.0% had a normal or slightly modified FLC ratio which corresponds to low and low-intermediate risk of disease progression, as opposed to 34.0% with an abnormal FLC ratio (<0.25 or >4) which corresponds to high and high-intermediate risk. An abnormal FLC ratio in the examined groups could be an independent risk factor for progression and poorer disease prognosis.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Kyle RA. Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med 1999; 123: 114-8.

  • Traynor AE Noga SJ. NCCN: Multiple myeloma. Cancer Control 2001; 8: 78-87.

  • Radović VV. Recommendations for use of free light chain assay in monoclonal gammopathies. Journal of Medical Biochemistry 2010; 29: 1-8

  • Turesson I. Monoclonal gammopathies. In: Diamandis EP Fritsche HA Lilja H Chan DW Schwartz MK eds. Tumor markers: physiology pathobiology technology and clinical applications. AACC Press Washington USA 2002; 305-19.

  • Alanakian MA Abbas A Delarue R Arnulf B Aucouturier P. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematology 2004; 75: 246-8.

  • Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805-7.

  • Rajkumar SV Kyle RA Thernearu TM Melton LJ III Bradwell AR Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-17.

  • Dispenzieri A Zhang L Katzmann JA Snyder M Blood E DeGoey R et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 4908-15.

  • Sirohi B Powles R Kulkarni S Rudin C Saso R Lal R et al. Comparison of new patients with Bence-Jones IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplantation. July (1) 2001; Volume 28 Number 1 Pages 29-37.

  • Snozek CLH Katzmann JA Kyle RA Dispenzieri A Larson DR Therneau TM et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008 October; 22 (10): 1933-7.

  • Bradwell AR Carr-Smith HD Mead GP Harvey TC Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-91.

  • Kyle RA Gertz MA Witzig TE Lust JA Lacy MQ Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.

  • Van Rhee F Bolejack V Hollmig K Pineda-Roman M Anaissie E Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-32.

  • Kyrtsonis MC Vassilakopoulos TP Kafasi N Sachanas S Tzenou T Papadogiannis A et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240-3.

  • Wintrobe's Clinical Haematology: Clinical Oncology 2nd Ed. Churchill Livingstone New York 2000.

  • Dispenzieri A Kyle R Merlini G Miguel JS Ludwig H Hajek R et al. International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia 2008; 23: 215-24.

  • Criteria for the classification of monoclonal gammopathies multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57.

  • Child JA Morgan GJ Davies FE Owen RG Bell SE Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.

  • Kyle RA Rajkumar SV. Monoclonal gammopathies of undetermined significance. In Hematology/Oncology Clinics of North America. Monoclonal Gammopathies & related disorders. Eds. RA Kyle & MA Gertz: W B Saunders Co. Philadelphia; 1999; 13: 1181-202.

  • Cavalo F Rasmussen E Zangari M Tricot G Fender B Fox M et al. Serum Free Light Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implication in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3). Blood 2005; 106 (11): 3490: p974a.

  • Baldini I Guffanti A Cesana BM Colombi M Chiorboli O Damilano I et al. Role of Different Hematologic Variables in Defining the Risk of Malignant Transformation in Monoclonal Gammopathy. Blood 1996; 87: 912-18.

  • Cojocaru M Cojocaru IM Silosi I Vrabie CD. Autoimmune lymphoproliferate syndrom. Journal of Medical Biochemistry 2010; 29: 15-18.

  • Rajkumar VS. MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis Natural History and Management. Hematology (Am Soc Hematol Educ Program). 2005; 340-5.

  • Kumar S Fonseca R Dispenzieri A Katzmann JA Kyle RA Clark R et al. High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels. ASH Annual Meeting Abstracts 2006; 108: 3514.

  • Radović V. Monoclonal gammopathy of undetermined significance and monoclonal free light chains of immunoglobulins. Arhiv za farmaciju 2010; 3: 285-96.

  • Mijušković Z Radović V Pejović J Tukić Lj Marjanović S. Free light chains ratio as a marker of the course and survival in plasmaproliferative diseases. Hematology Reports 2010; 2 (s2) 31.

Journal information
Impact Factor

IMPACT FACTOR 2018: 2.000
5-year IMPACT FACTOR: 1.075

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 223 159 1
PDF Downloads 78 59 1